AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.
BörsenkürzelRCEL
Name des UnternehmensAVITA Medical Inc
IPO-datumMar 18, 2012
CEOVance (Cary G)
Anzahl der mitarbeiter260
WertpapierartOrdinary Share
GeschäftsjahresendeMar 18
Addresse28159 Avenue Stanford
StadtVALENCIA
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl91355
Telefon16613679170
Websitehttps://www.avitamedical.com/
BörsenkürzelRCEL
IPO-datumMar 18, 2012
CEOVance (Cary G)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten